David Ilson, MD, PhD, discusses pre-operative chemotherapy alone versus chemotherapy plus radiation therapy in patients with esophageal and gastroesophageal-junction cancers, and how data points to the latter being the better choice.
Collective findings from clinical trials show that, for women with early-stage breast cancer who have a low 21-gene recurrence score, adding chemotherapy to standard hormonal therapy does not show a difference in survival.
In terms of neoadjuvant therapies for patients with HER2-positive breast cancer, dual anti–HER2-directed agents seem to have the most benefit.
Although there has been in increase in promising novel regimens available for patients with breast cancer in recent years, oncologists should carefully consider whether each agent would provide a significant enough benefit to offset its associated toxicities, cost, and the time and commitment by the patient it requires.
Ibrutinib (Imbruvica) and idelalisib (Zydelig) have become standard of care treatments for patients with relapsed or high-risk chronic lymphocytic leukemia, with ongoing studies in progress to move ibrutinib into the frontline setting.
Adam Bass, MD, discusses the various subclasses of gastric and esophageal cancer, mechanisms by which cancers are activated within a patient from dormancy, and the potential for uncovering an optimal treatment regimen for individual patients.
Two phase III trials examining afatinib (Gilotrif) in head and neck cancer have been stopped after an independent panel determined the pan-HER inhibitor was unlikely to demonstrate an efficacy benefit over placebo.
The pivotal phase III trial ARMOR 3-SV will be discontinued based on recommendations made by the trial's independent data monitoring committee.
The FDA granted daratumumab (Darzalex) a breakthrough therapy designation for use in combination with lenalidomide/dexamethasone or bortezomib/dexamethasone as a treatment for patients with multiple myeloma following at least 1 prior therapy.
The wide variability in clinical outcomes among patients undergoing anti–PD-1/PD-L1 immunotherapy has increased interest in finding biomarkers that predict response.